Kevin F. Jones

发表

LEGACY SYSTEMS’ SENSORS BECOME PLUG-N-PLAY WITH IEEE P1451.3 TEDS

Robert Sinclair, Charles H. Jones, Russell Beech, 2002 .

LEGACY SENSORS GO WIRELESS WITH IEEE P1451.5

Robert Sinclair, Charles H. Jones, Russell Beech, 2004 .

REMOVING OLD SENSOR MYSTERY WITH IEEE P1451.3 AND .4 STANDARDS

Robert Sinclair, Charles H. Jones, Russell Beech, 2003 .

Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase

Dennis E. Hruby, Chelsea M. Byrd, Dongcheng Dai, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection

Kevin F. Jones, R. Jordan, J. Leeds, 2013, PloS one.

A potent Lassa virus antiviral targets an arenavirus virulence determinant

Kevin F. Jones, M. J. Korth, M. Files, 2018, PLoS pathogens.

ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation

Kevin F. Jones, Robert H. Jordan, D. Hruby, 2009, Antimicrobial Agents and Chemotherapy.

Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.

Chelsea M. Byrd, Kevin F. Jones, D. Hruby, 2002, Vaccine.

Inactivation of the srtA Gene inStreptococcus gordonii Inhibits Cell Wall Anchoring of Surface Proteins and Decreases In Vitro and In Vivo Adhesion

Kevin F. Jones, D. Hruby, C. H. Jones, 2001, Infection and Immunity.

Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor

Kevin F. Jones, R. Jordan, D. Hruby, 2008, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of the Anti-Orthopoxvirus Compound ST-246 following a Single Daily Oral Dose for 14 Days in Human Volunteers

Kevin F. Jones, R. Jordan, J. Leeds, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Comparison of a Single Oral Dose of Polymorph Form I versus Form V Capsules of the Antiorthopoxvirus Compound ST-246 in Human Volunteers

Kevin F. Jones, R. Jordan, T. Marbury, 2012, Antimicrobial Agents and Chemotherapy.

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

Kevin F. Jones, R. Jordan, D. Hruby, 2009, Proceedings of the National Academy of Sciences.

Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects

Kevin F. Jones, R. Jordan, T. Marbury, 2010, Antimicrobial Agents and Chemotherapy.

Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

Kevin F. Jones, R. Jordan, D. Hruby, 2010, Vaccine.

Listeria monocytogenes 10403S HtrA Is Necessary for Resistance to Cellular Stress and Virulence

Kevin F. Jones, Rebecca L Wilson, D. Hruby, 2006, Infection and Immunity.

Analysis of Factors Affecting Surface Expression and Immunogenicity of Recombinant Proteins Expressed by Gram-Positive Commensal Vectors

Kevin F. Jones, V. Fischetti, D. Hruby, 2002, Infection and Immunity.

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses

Kevin F. Jones, M. Guttieri, Yuanming Zhang, 2005, Antiviral Research.

Comparison of the Safety and Pharmacokinetics of ST-246® after IV Infusion or Oral Administration in Mice, Rabbits and Monkeys

Kevin F. Jones, R. Jordan, J. Leeds, 2011, PloS one.

Evaluation of Lassa antiviral compound ST-193 in a guinea pig model

R. D. Allen, Kevin F. Jones, Mark A. Smith, 2011, Antiviral Research.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination

Kevin F. Jones, R. Jordan, D. Hruby, 2007, Vaccine.

Conserved DegP Protease in Gram-Positive Bacteria Is Essential for Thermal and Oxidative Tolerance and Full Virulence inStreptococcus pyogenes

Kevin F. Jones, D. Hruby, T. Bolken, 2001, Infection and Immunity.

Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine

Kevin F. Jones, V. Fischetti, S. Wasserman, 2005, Infection and Immunity.

Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge

Kevin F. Jones, D. Hruby, S. Lund, 2008, Journal of Virology.

Mucosal Vaccine Made from Live, Recombinant Lactococcus lactis Protects Mice against Pharyngeal Infection with Streptococcus pyogenes

Kevin F. Jones, P. Mannam, B. Geller, 2004, Infection and Immunity.

A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein

Chelsea M. Byrd, Kevin F. Jones, R. Bartenschlager, 2012, Antimicrobial Agents and Chemotherapy.

Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmid.

Kevin F. Jones, D. Hruby, S. Lund, 2007, Canadian journal of microbiology.

Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects (cid:1)

Kevin F. Jones, R. Jordan, T. Marbury, 2010 .

HelicaseReplication That Targets the NS3 Novel Benzoxazole Inhibitor of Dengue

Chelsea M. Byrd, Kevin F. Jones, J. Leeds, 2014 .

Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge

Kevin F. Jones, D. Hruby, S. Lund, 2008, Journal of Virology.